	Application No.	Applicant(s)
	10/574,639	THIRY ET AL.
Notice of Allowability	Examiner	Art Unit
	OLUWATOSIN OGUNBIYI	1645
	OLOWATOSIN OGONBITI	1043
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this a or other appropriate communicati IGHTS. This application is subject	application. If not included on will be mailed in due course. THIS
1. This communication is responsive to <u>1/5/2010</u> .		
2. The allowed claim(s) is/are <u>1,4,6,7,9-16,18-23,49,61-65,67,68,70,71,73-77,79,81 and 82</u> .		
3. Acknowledgment is made of a claim for foreign priority un	nder 35 U.S.C. § 119(a)-(d) or (f).	
a) ☑ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. 🛮 Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 🖂 Nation of Informa	I Detaut Auglication
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	5. ☐ Notice of Informa 6. ☑ Interview Summa	• •
_ , , ,	Paper No./Mail D	Date <u>20100122</u> .
3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 3/31/06	7. 🛛 Examiner's Amen	idment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	_	ment of Reasons for Allowance
	9. Other	
/Oluwatosin Ogunbiyi/		
Examiner, Art Unit 1645		

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Laurence Manber on 1/24/10.

Please Amend the Claims as follows:

- 7. (Currently Amended) An isolated or recombinant nucleic acid <u>encoding a</u>

 <u>Psp45 recombinant polypeptide</u>, wherein the isolated or recombinant nucleic acid

 <u>comprising comprises</u> the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3.
- 10. (Currently Amended) An <u>isolated</u> host cell that comprises the expression vector of claim 9.
- 62. (Currently Amended) An <u>isolated</u> host cell that comprises the expression vector of claim 61.
- 63. (Currently Amended) The <u>isolated</u> host cell of claim 62 wherein the host cell is an *E. coli* cell.
- 64. (Currently Amended) The immunogenic composition of claim 18 further comprising an antigen obtained from an Infectious Pancreatic Necrosis (IPN) virus,

Art Unit: 1645

wherein the antigen obtained from the IPN virus is selected from the group consisting of a VP2 var protein, [[aVP3]] <u>a VP3</u> protein, and a combination thereof.

65. (Currently Amended) The immunogenic composition of claim 19 further comprising an antigen obtained from an Infectious Pancreatic Necrosis (IPN) virus, wherein the antigen obtained from the IPN virus is selected from the group consisting of a VP2 var protein, [[aVP3]] a VP3 protein, and a combination thereof.

Information Disclosure Statement

The information disclosure statement filed 3/31/06 is corrected to include missing NPL dates and the corrected IDS has been considered.

Status of Claims

Claims 1, 4, 6-7, 9-16, 18-23, 49, 61-65, 67-68, 70-71, 73-77, 79 and 81-82 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLUWATOSIN OGUNBIYI whose telephone number is 571-272-9939. The examiner can normally be reached on M-F 8:30 am- 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/574,639 Page 4

Art Unit: 1645

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Oluwatosin Ogunbiyi/ Examiner, Art Unit 1645

/Robert B Mondesi/ Supervisory Patent Examiner, Art Unit 1645